Screener
Ligand Pharmaceuticals LGND Development and Licensing of Biopharmaceutical Assets — Depreciation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | Three months ended / June 30, 2026 | Three months ended / June 30, 2025 | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|---|---|
| Share-based compensation | (13,653) | (9,997) | (24,249) | (17,833) |
| Other segment items: | ||||
| Amortization of intangibles | (8,097) | (8,258) | (16,194) | (16,515) |
| Depreciation of property and equipment | (118) | (264) | (237) | (777) |
| Interest income | 7,298 | 1,621 | 13,953 | 3,392 |
| Interest expense | (1,748) | (1,153) | (3,495) | (2,020) |
| Other * | 1,133 | (24,729) | (50,030) | (96,811) |
| Net income (loss) | $48,508 | $4,847 | $35,163 | $(37,604) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation?
- Ligand Pharmaceuticals (LGND) reported development and licensing of biopharmaceutical assets — depreciation of $118K in Q2 2026.
- How has Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation changed year-over-year?
- Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation decreased by 55.3% year-over-year, from $264K to $118K.
- What is the long-term trend for Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation has grown at a -36.3% compound annual growth rate (CAGR), from $3.84M to $991K.
- What does development and licensing of biopharmaceutical assets — depreciation mean?
- This metric tracks the periodic allocation of the cost of tangible property and equipment used within the biopharmaceutical development and licensing segment. It accounts for the wear and tear or obsolescence of physical assets required to support operations. While generally a minor expense for this segment, it provides insight into the capital intensity of the business.
Ask your AI about Ligand Pharmaceuticals's development and licensing of biopharmaceutical assets — depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude